Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
ESSA Pharma Inc is a biotechnology business based in the US. ESSA Pharma shares (EPIX) are listed on the NASDAQ and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $1.79 |
|---|---|
| 52-week range | $1.66 - $14.88 |
| 50-day moving average | $2.71 |
| 200-day moving average | $6.36 |
| Wall St. target price | $23.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.87 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.79 from 2022-09-29
| 1 week (2022-09-23) | 2.29% |
|---|---|
| 1 month (2022-09-01) | -29.80% |
| 3 months (2022-07-01) | -36.52% |
| 6 months (2022-03-28) | N/A |
| 1 year (2021-10-01) | -78.56% |
|---|---|
| 2 years (2020-10-01) | -74.21% |
| 3 years (2019-10-01) | 3.05 |
| 5 years (2017-09-29) | 517.03% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -12.87% |
| Return on equity TTM | -20.12% |
| Profit margin | 0% |
| Book value | $3.89 |
| Market capitalisation | $75.8 million |
TTM: trailing 12 months
We're not expecting ESSA Pharma to pay a dividend over the next 12 months.
ESSA Pharma's shares were split on a 1:20 basis on 24 April 2018. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ESSA Pharma shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for ESSA Pharma shares which in turn could have impacted ESSA Pharma's share price.
Over the last 12 months, ESSA Pharma's shares have ranged in value from as little as $1.66 up to $14.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ESSA Pharma's is 1.5809. This would suggest that ESSA Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
ESSA Pharma Inc. , a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc. ; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.